阻断细胞周期:细胞周期蛋白依赖性激酶4/6抑制剂在转移性激素受体阳性乳腺癌中的应用
本文以一例68岁绝经后女性转移性激素受体阳性/HER2阴性乳腺癌病例为引,综述细胞周期蛋白依赖性激酶4/6抑制剂在该类患者中的诊断与管理挑战及相关文献,并总结作者建议的管理方法。
要点
- 病例为68岁绝经后女性,初诊II期(T2N1)浸润性导管癌,ER阳性、PR阳性、HER2阴性。
- 辅助来曲唑治疗6年期间出现骨转移及右锁骨上淋巴结转移,活检证实ER阳性(90%)、PR阴性、HER2阴性。
- 本文属 Oncology Grand Rounds 系列,旨在将期刊原始报告置于临床情境中并总结作者建议的管理方法。
核心结论
- 本文通过病例展示与文献回顾,总结作者对转移性激素受体阳性乳腺癌中细胞周期蛋白依赖性激酶4/6抑制剂应用的建议管理方法。
研究设计与样本
- Oncology Grand Rounds系列综述:以病例报告开场,随后描述诊断与管理挑战、回顾相关文献并总结作者建议的管理方法。
主要发现
- 患者6年前诊断为II期(T2N1)右侧浸润性导管癌,粗针活检分级为3级中的2级,同侧腋窝可触及淋巴结细针穿刺阳性。
- 免疫组化示雌激素受体和孕激素受体表达阳性、人表皮生长因子受体2(HER2)过表达阴性。
- 接受剂量密集多柔比星、环磷酰胺和紫杉醇新辅助化疗后行保乳手术及腋窝淋巴结清扫,11枚淋巴结中3枚见残留病变。
- 接受辅助放疗并开始来曲唑,6年间依从性极好;辅助来曲唑期间出现3个月腰背痛加重。
- 骨闪烁显像和横断面成像证实广泛骨转移及右锁骨上淋巴结增大,淋巴结粗针活检证实雌激素受体阳性(90%)、孕激素受体阴性、HER2阴性复发转移性乳腺癌。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 68-year-old postmenopausal woman was diagnosed with breast cancer 6 years ago when she presented with a stage II (T2N1), right-sided, invasive ductal carcinoma considered grade 2 of 3 on core biopsy, with a positive fine-needle aspiration of a palpable, ipsilateral axillary lymph node. Immunohistochemical analysis was positive for estrogen and progesterone receptor expression and negative for human epidermal growth factor receptor 2 (HER2) overexpression. She received neoadjuvant dose-dense doxorubicin, cyclophosphamide, and paclitaxel chemotherapy, followed by breast-conserving surgery and axillary lymph node dissection, which revealed residual disease in three of 11 nodes. She received adjuvant radiation therapy and initiated letrozole, with excellent compliance during the interval 6-year period. While receiving adjuvant letrozole therapy, she reported 3 months of worsening back pain. Skeletal scintigraphy and cross-sectional imaging confirmed widespread osseous metastatic disease and right supraclavicular lymph node enlargement ( Fig 1 ). Core biopsy of the involved lymph node confirmed estrogen receptor (ER)-positive (90%), progesterone receptor-negative, HER2-negative recurrent metastatic breast cancer. The patient reported mild pain that was adequately controlled with over-the-counter anti-inflammatory medications. She has remained active with an excellent performance status.
引用
- Wander SA, Mayer EL, Burstein HJ, et al. Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer. J Clin Oncol. 2017. PMID: 28580881. doi:10.1200/JCO.2017.73.9482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。